Neovasc Inc. (Neovasc) is a specialty medical device company. The Company develops, manufactures and markets products for the cardiovascular marketplace. The Company's segment is the development, manufacture and marketing of medical devices. Its products include the Tiara technology in development for the transcatheter treatment of mitral valve disease, the Neovasc Reducer for the treatment of refractory angina, and tissue products. The Tiara is in preclinical/early clinical stage development to provide a minimally invasive transcatheter device for patients experiencing mitral regurgitation (MR) as a result of mitral heart valve disease. The Reducer is an hourglass-shaped, balloon-expandable, stainless steel, bare metal device, which is implanted in the coronary sinus, creating a restriction in venous outflow from the myocardium (the muscular layer of the heart wall). Neovasc produces Peripatch, a biological tissue product that is manufactured from pericardium.
Industry, Sector and Symbol
Stock Exchange TSE
Industry N/A
Sub-IndustryN/A
SectorN/A
SymbolTSE:NVC
CUSIPN/A
Phone+1-604-2704344
Debt
Debt-to-Equity RatioN/A
Current RatioN/A
Quick RatioN/A
Price-To-Earnings
Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A
Sales & Book Value
Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / CashN/A
Book ValueN/A
Price / BookN/A
Profitability
EPS (Most Recent Fiscal Year)N/A
Net IncomeN/A
Net Margins-341.55%
Return on EquityN/A
Return on Assets-22.34%
Miscellaneous
EmployeesN/A
Outstanding Shares78,683,000
Market CapC$25.23 million
Neovasc (TSE:NVC) Frequently Asked Questions
What is Neovasc's stock symbol?
Neovasc trades on the Toronto Stock Exchange (TSX) under the ticker symbol "NVC."
When is Neovasc's next earnings date?
Who are Neovasc's key executives?
Neovasc's management team includes the folowing people:
- Paul L. Geyer, Independent Chairman of the Board
- Fred Colen, President, Chief Executive Officer
- Christopher Clark, Chief Financial Officer, Corporate Secretary
- Brian McPherson, Chief Operating Officer
- Vicki Lee Bebeau, Vice President - Clinical Affairs
- Randy Lane, Vice President - Research & Development
- Alexei J. Marko, Director
- Jane H. Hsiao Ph.D., Independent Director (Age 69)
- Douglas Glen Janzen, Independent Director
- William O'Neill, Independent Director (Age 61)
Has Neovasc been receiving favorable news coverage?
News coverage about NVC stock has trended somewhat positive this week, according to Accern Sentiment. The research group ranks the sentiment of news coverage by monitoring more than 20 million news and blog sources. Accern ranks coverage of public companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Neovasc earned a media and rumor sentiment score of 0.20 on Accern's scale. They also assigned headlines about the company an impact score of 48.06 out of 100, meaning that recent news coverage is somewhat unlikely to have an impact on the stock's share price in the immediate future. View Recent Headlines for Neovasc.
How do I buy shares of Neovasc?
Shares of NVC and other Canadian stocks can be purchased through online brokerage accounts that support trading on the Toronto Stock Exchange (TSX). Brokers that permit trading on the TSX include Fidelity, Interactive Brokers, PennTrade and Charles Schwab.
What is Neovasc's stock price today?
One share of NVC stock can currently be purchased for approximately C$1.78.
How big of a company is Neovasc?
Neovasc has a market capitalization of C$25.23 million.
How can I contact Neovasc?
Neovasc's mailing address is 13562 Maycrest Way Suite 5138, RICHMOND, BC V6V 2J7, Canada. The company can be reached via phone at +1-604-2704344.
MarketBeat Community Rating for Neovasc (TSE NVC)
MarketBeat's community ratings are surveys of what our community members think about Neovasc and other stocks. Vote "Outperform" if you believe NVC will outperform the S&P 500 over the long term. Vote "Underperform" if you believe NVC will underperform the S&P 500 over the long term. You may vote once every thirty days.
